Analysts Set LivaNova PLC (NASDAQ:LIVN) Target Price at $70.80

Shares of LivaNova PLC (NASDAQ:LIVN) have been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $70.80.

Several brokerages have issued reports on LIVN. Needham & Company LLC raised their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $55.00 to $66.00 in a report on Tuesday, September 17th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Stifel Nicolaus increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th.

LivaNova Stock Down 0.9 %

LIVN stock opened at $50.75 on Thursday. LivaNova has a twelve month low of $42.75 and a twelve month high of $64.47. The company has a market cap of $2.75 billion, a price-to-earnings ratio of -84.58 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average price of $48.85 and a two-hundred day moving average price of $53.38.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $318.60 million during the quarter, compared to analysts’ expectations of $305.05 million. Analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently bought and sold shares of the company. Hexagon Capital Partners LLC raised its holdings in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after acquiring an additional 332 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of LivaNova in the 1st quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova during the 2nd quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new position in LivaNova during the 1st quarter worth approximately $94,000. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.